Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3344071 | 1.00 | AOC3 (0.46) | AOC3TSHREPHX1KDM4EMEN1 | |
| SCHEMBL3661053 | 0.78 | EPHX1 (0.56) | TSHREPHX1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3342998 | 0.77 | TSHR (0.49) | TSHREPHX1KDM4EMEN1KMT2A | |
| SCHEMBL3343000 | 0.77 | TSHR (0.49) | TSHREPHX1KDM4EMEN1KMT2A | |
| SCHEMBL2093623 | 0.75 | AOC3 (0.61) | AOC3KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16901650 | 0.75 | AOC3 (0.61) | AOC3KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4583626 | 0.75 | AOC3 (0.61) | AOC3KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14393835 | 0.75 | AOC3 (0.61) | AOC3KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14269872 | 0.75 | TSHR (0.44) | TSHREPHX1MEN1KMT2ATP53 | |
| SCHEMBL14260866 | 0.75 | TSHR (0.44) | TSHREPHX1MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858776-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2010-12-28 | — | — | US | disclosed |
| US-20100160627-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-20090054398-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7294622-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2007-11-13 | — | — | US | disclosed |
| EP-1845089-A1 | Novel lactams and uses thereof | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1554250-B1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| US-20060089346-A1 | Novel lactams and uses thereof | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | disclosed |
| EP-0414020-B1 | Process for the preparation of clausenamide and neoclausenamide and their derivatives | BAYER AG (DE) | 1994-09-21 | — | — | EP | disclosed |
| US-5132433-A | PROCESS FOR THE PREPARATION OF CLAUSENAMIDE AND NEOCLAUSENAMIDE, AND DERIVATIVES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 1992-07-21 | — | — | US | disclosed |
| US-5093350-A | DEHYDROCYCLOCLAUSENAMIDE, ITS PREPARATION AND USE IN TREATING CEREBRAL HYPOXIA | BAYER AKTIENGESELLSCHAFT (DE) | 1992-03-03 | — | — | US | disclosed |
| EP-0414020-A2 | Process for the preparation of clausenamide and neoclausenamide and their derivatives | BAYER AG (DE) | 1991-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089346-A1 | Novel lactams and uses thereof | BACE1, BACE2, APH1B | AOC3 2924/4885TSHR 4728/4885EPHX1 1669/4885 |
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | APP, BACE1, PSEN1 | AOC3 2571/4885TSHR 4423/4885EPHX1 905/4885 |
| US-20100160627-A1 | NOVEL LACTAMS AND USES THEREOF | BACE1, BACE2, APP | AOC3 2867/4885TSHR 4717/4885EPHX1 1674/4885 |
| US-20090054398-A1 | CHEMICAL COMPOUNDS | NOTCH1, HES1, NOTCH2 | AOC3 4557/4885TSHR 3858/4885EPHX1 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.